UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000040562
Receipt number R000046273
Scientific Title Brigatinib biomarker study for ROS1-fusion positive cancer
Date of disclosure of the study information 2020/05/28
Last modified on 2020/05/28 10:44:55

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Brigatinib biomarker study for ROS1-fusion positive cancer

Acronym

Barossa biomarker study

Scientific Title

Brigatinib biomarker study for ROS1-fusion positive cancer

Scientific Title:Acronym

Barossa biomarker study

Region

Japan


Condition

Condition

solid tumor

Classification by specialty

Gastroenterology Hepato-biliary-pancreatic medicine Pneumology

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

This study is an adjunct study to basket study of brigatinib in patients with advanced solid tumors with ROS1 rearrangement, and the efficacy of brigatinib using patient samples (tumor tissue and plasma) enrolled in the study and clarify the molecular mechanism involved in resistance.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

To evaluate the relationship between the gene abnormalities before, during, and after treatment with brigatinib and the therapeutic effect, and to explore the molecular mechanism related to the efficacy and resistance of brigatinib in ROS1 fusion gene-positive solid tumors.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Gene panel performance confirmation part:
1) Patients enrolled in prospective observational study to clarify genetic abnormalities in lung cancer and their clinicopathologic, molecular biological characteristics, and resistance mechanism of cancer therapeutic agents.
2) Secondary use of specimens by using a written consent document explaining prospective observational study to clarify genetic abnormalities in lung cancer and their clinicopathologic, molecular biological characteristics, and resistance mechanism of cancer therapeutic agents, And there are enough samples to carry out the genetic analysis of this study.
3) Patients with ROS1 rearrangement positive lung cancer or ROS1 rearrangement negative lung cancer
Efficacy / resistance analysis part:
1) Cases registered in basket study
of brigatinib in patients with advanced solid tumors with ROS1 rearrangement.
2) Among the subjects who obtained consent to provide samples for the accompanying study using the informed consent document of basket study of brigatinib in patients with advanced solid tumors with ROS1 rearrangement, There are enough samples to perform the analysis.

Key exclusion criteria

non

Target sample size

72


Research contact person

Name of lead principal investigator

1st name Koichi
Middle name
Last name Goto

Organization

National Cancer Center Hospital East

Division name

Department of Thoracic Oncology

Zip code

277-8577

Address

6-5-1, Kashiwanoha, Kashiwa, Chiba, Japan

TEL

04-7133-1111

Email

kgoto@east.ncc.go.jp


Public contact

Name of contact person

1st name Takaya
Middle name
Last name Ikeda

Organization

National Cancer Center Hospital East

Division name

Department of Thoracic Oncology

Zip code

277-8577

Address

6-5-1, Kashiwanoha, Kashiwa, Chiba, Japan

TEL

04-7133-1111

Homepage URL


Email

takikeda@east.ncc.go.jp


Sponsor or person

Institute

National Cancer Center Hospital East

Institute

Department

Personal name



Funding Source

Organization

Takeda Pharmaceutical Company

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Cancer Center Hospital East

Address

6-5-1, Kashiwanoha, Kashiwa, Chiba, Japan

Tel

04-7133-1111

Email

irst@ml.res.ncc.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

国立がん研究センター東病院、国立がん研究センター中央病院、九州がんセンター、岡山大学病院、鳥取大学、兵庫県立がんセンター、大阪市立総合医療センター、名古屋大学、静岡県立静岡がんセンター、新潟県立がんセンター新潟病院、北海道大学


Other administrative information

Date of disclosure of the study information

2020 Year 05 Month 28 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2020 Year 02 Month 06 Day

Date of IRB

2020 Year 02 Month 12 Day

Anticipated trial start date

2020 Year 03 Month 03 Day

Last follow-up date

2023 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded

2023 Year 03 Month 31 Day


Other

Other related information

This study is a observational study.


Management information

Registered date

2020 Year 05 Month 28 Day

Last modified on

2020 Year 05 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046273


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name